Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be webcast: Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13 at 11:10 am ET (8:10 am PT/4:10 pm IST) H.C.

Theravance Biopharma to Present at Upcoming Investor Conferences

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2022 Conference Call.

Theravance Biopharma, Inc.'s (TBPH) CEO Rick Winningham on Q2 2022 Results - Earnings Call Transcript

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Royalty Pharma

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA filing with one additional Phase 3 clinical study in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash with over $1.5 billion in total potential value Launched tender offer for outstanding 3.25% Convertible Senior Notes  DUBLIN , Aug. 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2022. "The Company has continued to execute on its strategy and, since the first quarter, we have accomplished several transformative goals.

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

DUBLIN , July 26, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a tender offer (the "Offer") to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the "Convertible Notes"). As of July 26, 2022, there were $230,000,000 aggregate principal amount of the Convertible Notes outstanding.

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva?

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

Shares of Theravance Biopharma Inc. TBPH, -0.80% were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's GSK, -1.25% Trelegy Ellipta to Royalty Pharma RPRX, -0.40% for $1.1 billion in cash and up to $450 million in potential milestone payments. Trelegy Ellipta is a treatment for asthma and chronic obstructive pulmonary disease.

Theravance sets up deal to sell rights to asthma drug to Royalty Pharma

Innoviva

Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc's (NYSE: GSK) TRELEGY ELLIPTA to Royalty.

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1 Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm IST DUBLIN , July 13, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA ("TRELEGY") to Royalty Pharma (NASDAQ: RPRX) for over $1.5 billion in potential total value (the "TRELEGY Royalty Transaction"). The transaction is intended to provide near-, mid- and long-term value to the Company with an upfront cash payment of approximately $1.1 billion, up to $250 million in additional milestone payments contingent on the achievement of certain TRELEGY net sales thresholds between 2023 and 2026 and outer year royalties to the Company providing an opportunity to receive an estimated NPV of approximately $200 million.1 Immediately after announcing the TRELEGY Royalty Transaction, Theravance Biopharma intends to initiate a multi-step process to eliminate its outstanding debt and return capital to shareholders.

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President and Chief Business Officer Rick Graham – Senior Vice President-Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Ben Ricard – Needham & Company David Risinger – SVB Securities Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2022 Conference Call.

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2022 Results -Earnings Call Transcript

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

Implied 35% share of YUPELRI® (revefenacin) net sales1 : $15.3M Q1 2022 up 19% from Q1 2021 TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212 Results from a Phase 3 study of ampreloxetine showed a benefit in study patients with multiple system atrophy (MSA) Restructuring process completed in Q1 2022 DUBLIN , May 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022. "We continue to execute against our business plan, stay disciplined in capital allocation, and 2022 remains on track to become sustainably cash-flow positive by the second half of this year  and going forward on an annual basis," said Rick E Winningham, Chief Executive Officer.

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

Theravance's (TBPH) Hypotension Study Misses Primary Goal

Theravance Biopharma Inc (NASDAQ: TBPH) revealed results from the second Phase 3 study assessing ampreloxetine compared to placebo for symptomatic nOH.  Neurogenic orthostatic hypotension (nOH) is a rare disorder defined as a sustained orthostatic fall in blood pressure within.

Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistically significant for the overall population of patients. The overall population .

Why Theravance Biopharma Stock Is Trading Lower After Hours

Results from Study 0170 show a benefit in study patients with multiple system atrophy (MSA) Company beginning discussions with potential strategic partners and planning health authority interactions to expedite ampreloxetine as a possible treatment option for patients with symptomatic nOH Company remains focused on respiratory therapeutics, value creation for shareholders and reiterates plan to be sustainably cash-flow positive by the second half of the year DUBLIN , April 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced results from the second Phase 3 study, Study 0170 (n=128 out of n=154 planned), assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic nOH. Study 0170 was a 22-week Phase 3 study comprised of a 16-week open-label period followed by a 6-week double-blind, placebo-controlled, randomized withdrawal period.

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q4 2021 Results - Earnings Call Transcript

News for Theravance Biopharma Stock (TBPH)